Search results for "SARS"

showing 10 items of 1372 documents

Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19☆

2020

Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-C…

0301 basic medicinemedicine.medical_specialtyVitamina Cmedicine.drug_classLung injurymedicine.disease_causeArticle03 medical and health sciences0302 clinical medicineOzoneIntensive caremedicineAdjuvant therapyVitamin CIntensive care medicineOzonoCoronavirusbusiness.industrySARS-CoV-2COVID-19030208 emergency & critical care medicineGeneral MedicineAscorbic acidmedicine.diseaseClinical trialPneumonia030104 developmental biologyAntiviral drugbusinessRevista Española de Anestesiología y Reanimación (English Edition)
researchProduct

Symptomatic COVID-19 in advanced-cancer patients treated with immune-checkpoint inhibitors. Prospective analysis from a multicentre observational tri…

2020

Background:This prospective, multicentre, observational INVIDIa-2 study is investigating the clinical efficacy of influenza vaccination in advanced-cancer patients receiving immune-checkpoint inhibitors (ICIs), enrolled in 82 Italian centres, from October 2019 to January 2020. The primary endpoint was the incidence of influenza-like illness (ILI) until 30 April 2020. All the ILI episodes, laboratory tests, complications, hospitalizations and pneumonitis were recorded. Therefore, the study prospectively recorded all the COVID-19 ILI events.Patients and methods:Patients were included in this non-prespecified COVID-19 analysis, if alive on 31 January 2020, when the Italian government declared …

0301 basic medicinemedicine.medical_specialtymedicine.medical_treatmentimmune-checkpoint inhibitorsinfluenza-like illnesslcsh:RC254-28203 medical and health sciences0302 clinical medicineCancer immunotherapyInternal medicineMedicineProspective cohort studyCancer stagingOriginal ResearchInfluenza-like illnessbusiness.industrySARS-CoV-2virus diseasesCOVID-19Immunotherapycancer patients; COVID-19; immune-checkpoint inhibitors; influenza-like illness; SARS-CoV-2lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseComorbidityVaccination030104 developmental biologyOncology030220 oncology & carcinogenesisObservational studybusinesscancer patients
researchProduct

Does Evidence Exist to Blunt Inflammatory Response by Nutraceutical Supplementation during COVID-19 Pandemic? An Overview of Systematic Reviews of Vi…

2021

More than one year has passed since the first cases of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome (SARS)-CoV-2 coronavirus were reported in Wuhan (China), rapidly evolving into a global pandemic. This infectious disease has become a major public health challenge in the world. Unfortunately, to date, no specific antivirals have been proven to be effective against COVID-19, and although a few vaccines are available, the mortality rate is not decreasing but is still increasing. One therapeutic strategy has been focused on infection prevention and control measures. In this regard, the use of nutraceutical supports may play a role against some aspect of the i…

0301 basic medicinemedicine.medical_specialtyoverviewvitamin Clcsh:TX341-641vitamin DmelatoninAscorbic AcidCochrane LibraryMelatonin03 medical and health sciences0302 clinical medicineNutraceuticalImmune systemMeta-Analysis as Topicsystematic reviewInternal medicineVitamin D and neurologyMedicineInfection controlHumans030212 general & internal medicinenutraceuticalsNutrition and DieteticsVitamin Cbusiness.industrySARS-CoV-2zincCOVID-19VitaminsTrace ElementsCOVID-19 Drug Treatment030104 developmental biologySystematic reviewC-Reactive ProteininflammationImmune SystemDietary Supplementsbusinesslcsh:Nutrition. Foods and food supplyFood Sciencemedicine.drug
researchProduct

Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection

2021

Apart from prevention using vaccinations, the management options for COVID-19 remain limited. In retrospective cohort studies, use of famotidine, a specific oral H2 receptor antagonist (antihistamine), has been associated with reduced risk of intubation and death in patients hospitalized with COVID-19. In a case series, nonhospitalized patients with COVID-19 experienced rapid symptom resolution after taking famotidine, but the molecular basis of these observations remains elusive. Here we show using biochemical, cellular, and functional assays that famotidine has no effect on viral replication or viral protease activity. However, famotidine can affect histamine-induced signaling processes i…

0301 basic medicinemedicine.medical_treatmentPharmacologyVirus ReplicationBiochemistrychemistry.chemical_compoundChemokine CCL2Coronavirus 3C ProteasesResearch ArticlesToll-like receptorbiologyNF-kappa BFamotidineMolecular Docking SimulationCytokine release syndromeCytokinemedicine.symptomSignal transductionHistaminemedicine.drugProtein BindingSignal TransductionHistamine AntagonistsInflammation03 medical and health sciencesToll-like receptormedicineHumansInterleukin 6Molecular BiologyBinding Sites030102 biochemistry & molecular biologybusiness.industryInterleukin-6SARS-CoV-2Cell Biologymedicine.diseasehistamineToll-Like Receptor 3Famotidine030104 developmental biologychemistryA549 CellsSARS-CoV2biology.proteinanti-viral signalingInterferon Regulatory Factor-3Caco-2 CellsbusinessHeLa Cells
researchProduct

De Novo Genome Assembly of the Raccoon Dog (Nyctereutes Procyonoides)

2021

The raccoon dog, Nyctereutes procyonoides (NCBI Taxonomy ID: 34880, Figure 1a) belongs to the family Canidae, with foxes (genus Vulpes) being their closest relatives (Lindblad-Toh et al., 2005; Sun et al., 2019). Its original distribution in East Asia ranges from south-eastern Siberia to northern Vietnam and the Japanese islands. In the early 20th century, the raccoon dog was introduced into Western Russia for fur breeding and hunting purposes, which led to its widespread establishment in many European countries, Figure 1b. Together with the raccoon (Procyon lotor), it is now listed in Europe as an invasive species of Union concern (Regulation (EU) No. 1143/2014) and member states are requi…

0301 basic medicinepopulation genomicsRange (biology)ZoologyB chromosomeQH426-470GenomePopulation genomics03 medical and health sciences0302 clinical medicineddc:590Data ReportGeneticsraccoon dog (nyctereutes procyonoides)IUCN Red Listmedia_common.cataloged_instanceGenetics (clinical)Syntenymedia_commonB chromosomebiologySARS-CoV-2sequencebiology.organism_classificationgenome assembly and annotationanimalsCanis lupus familiaris030104 developmental biology030220 oncology & carcinogenesisrangeMolecular MedicinecarnivoraNyctereutes procyonoides
researchProduct

Application of a portable instrument for rapid and reliable detection of SARS-CoV-2 infection in any environment

2020

Abstract The ongoing outbreak of the novel coronavirus (SARS‐CoV‐2) infection is creating serious challenges for health laboratories that seek to identify viral infections as early as possible, optimally at the earliest appearance of symptom. Indeed, there is urgent need to develop and deploy robust diagnostic methodologies not only to use in health laboratory environments but also directly in places where humans circulate and spread the virus such as airports, trains, boats, and any public aggregation places. The success of a reliable and sensitive asymptomatic diagnosis relies on the identification and measurement of informative biomarkers from human host and virus in a rapid, sensitive, …

0301 basic medicineportableSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralImmunologycoronavirusBiologymedicine.disease_causeSensitivity and SpecificityDisease OutbreaksWorkflowBetacoronavirus03 medical and health sciencesCOVID-19 Testing0302 clinical medicinePandemicmedicineAnimalsHumansMass ScreeninginstrumentImmunology and AllergyBiomarker discoveryAsymptomatic InfectionsPandemicsdeviceMass screeningCoronavirusInvited ReviewClinical Laboratory TechniquesSARS-CoV-2COVID-19Reproducibility of ResultsClinical Laboratory Servicescoronavirus; device; instrument; portable; SARS-CoV-2 detection; Animals; Asymptomatic Infections; Betacoronavirus; Biomarkers; Clinical Laboratory Services; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Mass Screening; Pandemics; Pneumonia Viral; Reproducibility of Results; Sensitivity and Specificity; WorkflowIdentification (information)030104 developmental biologyWorkflowRisk analysis (engineering)SARS‐CoV‐2 detectionCoronavirus InfectionsHost (network)Biomarkers030215 immunology
researchProduct

Do genetic polymorphisms in angiotensin converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)?

2020

Abstract Although some demographic, clinical and environmental factors have been associated with a higher risk of developing coronavirus disease 2019 (COVID-19) and progressing towards severe disease, altogether these variables do not completely account for the different clinical presentations observed in patients with comparable baseline risk, whereby some subjects may remain totally asymptomatic, whilst others develop a very aggressive illness. Some predisposing genetic backgrounds can hence potentially explain the broad inter-individual variation of disease susceptibility and/or severity. It has been now clearly established that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2…

0301 basic medicinereceptorClinical BiochemistryPopulationPneumonia ViralAdipose tissueInflammationPeptidyl-Dipeptidase AAsymptomaticViruspolymorphism03 medical and health sciencesBetacoronavirus0302 clinical medicineProtein DomainsFibrosismedicineHumans030212 general & internal medicineeducationGenePandemicseducation.field_of_studyPolymorphism Geneticbusiness.industrySARS-CoV-2Biochemistry (medical)COVID-19General Medicineangiotensinmedicine.diseaseenzyme030104 developmental biologyCOVID-19 angiotensin enzyme polymorphism receptorImmunologyAngiotensin-converting enzyme 2Spike Glycoprotein CoronavirusReceptors VirusAngiotensin-Converting Enzyme 2medicine.symptombusinessCoronavirus InfectionsProtein Binding
researchProduct

Statistical Explorations and Univariate Timeseries Analysis on COVID-19 Datasets to Understand the Trend of Disease Spreading and Death

2020

&ldquo

0301 basic medicinetransmission ratepopulationSevere Acute Respiratory Syndromemedicine.disease_causelcsh:Chemical technologyBiochemistryRNNDisease OutbreaksAnalytical Chemistry0302 clinical medicinePandemiclcsh:TP1-1185030212 general & internal medicineInstrumentationVDP::Teknologi: 500::Informasjons- og kommunikasjonsteknologi: 550Coronaviruskeraseducation.field_of_studypublic healthartificial intelligenceAtomic and Molecular Physics and OpticsRegressionmachine learningGeographySevere acute respiratory syndrome-related coronavirusstatisticsMiddle East Respiratory Syndrome Coronaviruscommunity diseaseregressionCoronavirus InfectionsLSTMPneumonia ViralPopulationWorld Health OrganizationArticleBetacoronavirusspread factor03 medical and health sciencesCode (cryptography)medicineAnimalsHumansElectrical and Electronic EngineeringeducationPandemicsmeasurable sensor dataalgorithmSARS-CoV-2ICDUnivariatedeep learningOutbreakCOVID-19medicine.diseasehypothesis testpython030104 developmental biologycorrelationCatsMiddle East respiratory syndromeCattleDemographySensors
researchProduct

Guidelines Have a Key Role in Driving HCV Elimination by Advocating for Simple HCV Care Pathways.

2021

The availability of pangenotypic direct-acting antivirals for treatment of hepatitis C (HCV) has provided an opportunity to simplify patient pathways. Recent clinical practice guidelines have recognised the need for simplification to ensure that elimination of HCV as a public health concern remains a priority. Despite the move towards simplified treatment algorithms, there remains some complexity in the recommendations for the management of genotype 3 patients with compensated cirrhosis. In an era where additional clinical trial data are not anticipated, clinical guidance should consider experience gained in real-world settings. Although more experience is required for some pangenotypic the…

030213 general clinical medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)EliminationGuidelineGuidelinesGlobal HealthAntiviral AgentsPatient pathwaySimplification03 medical and health sciences0302 clinical medicinePandemicGlobal healthMedicineHumansPharmacology (medical)Disease EradicationIntensive care medicineAntiviral Agentbusiness.industrySARS-CoV-2Public healthCOVID-19General MedicineHepatitis CHcv eliminationClinical trialCritical Pathway030220 oncology & carcinogenesisCommunicable Disease ControlPractice Guidelines as TopicKey (cryptography)Critical PathwaysCommentarybusinessHumanAdvances in therapy
researchProduct

The first wave of the Spanish COVID-19 epidemic was associated with early introductions and fast spread of a dominating genetic variant

2020

The COVID-19 pandemic has shaken the world since the beginning of 2020. Spain is among the European countries with the highest incidence of the disease during the first pandemic wave. We established a multidisciplinar consortium to monitor and study the evolution of the epidemic, with the aim of contributing to decision making and stopping rapid spreading across the country. We present the results for 2170 sequences from the first wave of the SARS-Cov-2 epidemic in Spain and representing 12% of diagnosed cases until 14th March. This effort allows us to document at least 500 initial introductions, between early February-March from multiple international sources. Importantly, we document the …

0303 health sciences03 medical and health sciences2019-20 coronavirus outbreak0302 clinical medicineGeographyCoronavirus disease 2019 (COVID-19)Research councilSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Genetic variantsLibrary science030212 general & internal medicine030304 developmental biology3. Good health
researchProduct